Skip to main content

Tweets

Phase 3 RCT shows that SC Abatacept was not effective in treating Active Idiopathic Inflammatory Myopathy: 148 (double-blind) & 133 (OL) pts Rx for 24wks with similar improvement 56% ABA vs 42.5% PBO (P = 0.083); NS at 52 wks & w/ dermatomyositis. https://t.co/InlHJSmiKn https://t.co/mtFQWp3vlb
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 2 days ago
EUSTAR database study of 17,805 scleroderma (SSc) pts, 468 (2.6%) used HCQ with no effect on or improvement on HAQ-DI, or hand function scores when comparing HCQ users to non-HCQ users. https://t.co/Tu4tfG74pn https://t.co/Kckx3zTiJ4
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 2 days ago
Fresenius Receives FDA Approval for their Denosumab Biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) based on reference products: Prolia (denosumab) and Xgeva (denosumab) respectively. US launch mid-2025 https://t.co/0i5ZMJSxnp https://t.co/zeQ7QhmA0n
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 2 days ago
Rheums! Have a rheumatology question or case for Dr.Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/VkPL7thzo8 https://t.co/h85iF6tIVk
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 2 days ago
Full read review on inflammatory myositis (Patient or med student level knowlegdge) Epidemiology Risk Factors Prognosis Sxs, Dx, Differential Dx Treatment Complications Myositis Guidelines https://t.co/s0LtHyYeuS https://t.co/lMEpMIotSP
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 2 days ago
Missed RheumNow Live but still want the great coverage? For the first time ever, https://t.co/4UQlqwujiR 2025 is Available On Demand! ✔️ STEP Talks from top rheumatologists ✔️ Lectures on the biggest clinical challenges ✔️ Speaker slides and handouts you’ll use Non-CME, https://t.co/lns8EQBZjw
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 2 days ago
Worse Outcomes in HLA-B27+ JIA Patients with juvenile idiopathic arthritis (JIA) who carried the HLA-B27 genetic marker tended to have worse long-term outcomes, including lower rates of drug-free remission, in a prospective Scandinavian study. https://t.co/VEKqHvO1qw https://t.co/49y0JQL0Gr
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 2 days ago
Peripheral Nerve Blocks for Hip Fractures JAMA reviews the use of peripheral nerve block with hip fractures as an effective pain management strategy that can be performed by credentialed clinicians outside of the operating room. https://t.co/baeLWVxeUo https://t.co/ZBTVDT0jGR
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 3 days ago
A comprehensive examination of the pathogenesis and recent advancements in Familial Mediterranean Fever (FMF). This condition results from autosomal recessive mutations in the MEFV gene, which codes for Pyrin, a crucial component of the NLRP3 inflammasome. These genetic https://t.co/XNV89LW893
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 3 days ago
A study in mice shows that JAK inhibition In mice model of status epilepticus (SE) didnt prevent initial SE but when did effect chronic phase of Sz weeks after SE induction of SE, suppressing seizures, and epilepsy-associated histopathological alterations. Sz suppression lasted https://t.co/GMIPCtoc7x
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 4 days ago
ACPA specificity and recognition motifs examined in 6,907 patients with RA from 5 Scandinavian cohorts. ACPA targeting non-glycine citrulline motifs assoc. more strongly w/ HLA-SE; ACPA to glycine citrulline motifs assoc. w/ smoking and IgA ACPA A&R https://t.co/PmKv3dZLc4 https://t.co/NdPG4Orfj4
ACR_Journals @ACR_Journals ( View Tweet )
3 weeks 4 days ago
Autoimmune Disease Impact Report Integrated Benefit Institute, a nonprofit independent research organization, has published its 2025 Autoimmune Disease Impact Report, which examines the health and productivity impacts of five prevalent and costly autoimmune conditions: https://t.co/TfXZti5NN3
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 4 days ago
×